Biotie Therapies - Notice to general meeting

INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.

BIOTIE  THERAPIES CORP.       STOCK EXCHANGE RELEASE              12 April 2016
at 9.00 a.m. (EET)



INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.

Notice  is given  to the  shareholders of  Biotie Therapies  Corp. of the Annual
General  Meeting of the company  to be held on  3 May 2016 at 2.00 p.m. (Finnish
time)  at Joukahaisenkatu 3-5 (ICT-building,  Alpha auditorium), Turku, Finland.
The  reception  of  shareholders  who  have  registered  for the meeting and the
distribution of voting tickets will commence at 1.30 p.m. (Finnish time).

Acorda Therapeutics, Inc. ("Acorda") has on 11 April 2016 announced that it will
complete  the tender offer  for all of  the outstanding shares  and other equity
securities  issued  by  Biotie  Therapies  Corp.  and accept all such securities
tendered  into the tender offer  as of the expiration  of the tender offer on 8
April  2016 at  4 p.m.  (Finnish  time).  On 11 April 2016, Acorda announced the
preliminary  results of  the tender  offer, including  that approximately 93.77
percent  of all  the shares  and votes  in Company  on a  fully-diluted basis as
defined in the terms and conditions of the tender offer had been tendered. It is
therefore expected that Acorda will come to hold approximately 92.37 percent  of
all  the shares and  votes in Biotie  Therapies Corp. (excluding treasury shares
held  by the  Company) upon  the closing  of the  tender offer on 18 April 2016
(prior  to the Annual General  Meeting of the company).  Acorda has informed the
Board  of  Directors  of  certain  proposals  that  Acorda  intends  make  as  a
shareholder  at the Annual General  Meeting, which are set  forth below in Items
10-12 and 14.

A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING

At the Annual General Meeting, the following matters will be considered:

1. Opening of the meeting

2. Calling the meeting to order

3. Election  of persons to confirm the minutes  and to supervise the counting of
votes

4. Recording the legality of the meeting

5. Recording the attendance at the meeting and adoption of the list of votes

6. Presentation  of  the  financial  statements,  the  report  of  the  Board of
Directors and the auditor's report for the year 2015

7. Adoption of the financial statements

8. Booking of the result of the financial year

The  Board of Directors proposes  that no dividend for  the financial year 2015
will  be paid and that the losses of  the parent company for the financial year,
amounting  to EUR  5,2 million (FAS),  will be  carried forward to shareholders'
equity.

9. Resolution  on the discharge of the members of the Board of Directors and the
Managing Director from liability

10. Resolution on the remuneration of the members of the Board of Directors

Acorda  has informed the Board  of Directors that it  intends to propose that no
remuneration  is payable to board members.  Reasonable travel and other expenses
related to Board work are proposed to be covered by the company.

11. Resolution on the number of members of the Board of Directors

Acorda  has informed the Board of Directors  that it intends to propose that the
number of members of the Board of Directors would be three (3).

12. Election of members of the Board of Directors

Acorda  has informed the Board of Directors  that it intends to propose that the
following  individuals be elected as  members of the Board  of Directors for the
term  expiring at the  end of the  following Annual General  Meeting: Ron Cohen,
Michael Rogers and Jane Wasman. Candidates for Board members have been presented
on the Company's web site.

Acorda  has informed the Board of Directors  that these persons have given their
consent to serve on the Board of Directors of Biotie.

13. Resolution on the remuneration of the auditors

The  Board of Directors proposes that the  auditors' fees would be paid pursuant
to a reasonable invoice.

14. Election of the auditors

Acorda  has informed the Board of Directors  that it intends to propose that the
number  of auditors would be resolved to be one (1) and that Ernst & Young Oy, a
firm  of Authorized Public Accountants,  would be elected as  the auditor of the
company.

15. Closing of the meeting

B. DOCUMENTS OF THE ANNUAL GENERAL MEETING

The  proposals relating to the  agenda of the Annual  General Meeting as well as
this notice are available on Biotie Therapies Corp.'s website at www.biotie.com.
In  addition, Biotie Therapies  Corp.'s financial statements,  the report of the
Board of Directors and the auditor's report are available on the above-mentioned
website.  The proposals of  the Board of  Directors and the financial statements
are  also available at the meeting. Copies of these documents and of this notice
will  be sent to shareholders  upon request. The minutes  of the meeting will be
available on the above-mentioned website as of 17 May 2016.

C. INSTRUCTIONS FOR THE PARTICIPANTS IN THE ANNUAL GENERAL MEETING

1. The right to participate and registration

Each  shareholder,  who  is  registered  on  21 April  2016 in the shareholders'
register  of  the  company  held  by  Euroclear  Finland  Ltd,  has the right to
participate  in  the  Annual  General  Meeting.  A shareholder, whose shares are
registered  on his or her personal  Finnish book-entry account, is registered in
the shareholders' register of the company.

A shareholder registered in the shareholders' register of the company, who wants
to  participate in the Annual General Meeting, shall register for the meeting by
giving  a prior notice of participation by  no later than 28 April 2016 at 4.00
p.m.  (Finnish time) by which time the notice needs to have arrived. Such notice
can be given:

a) through the company's website at www.biotie.com;
b) by e-mail to virve.nurmi@biotie.com;
c) by telephone +358 2 274 8911; or
d) by regular mail to Biotie Therapies Corp. / Virve Nurmi, Joukahaisenkatu 6,
FI-20520 Turku, Finland.

In  connection with the  registration, the shareholder  shall provide his or her
name,  personal identification number, address, telephone number and the name of
any  possible assistant or proxy  representative and the personal identification
number  of such an assistant or proxy representative. The personal data given to
Biotie  Therapies Corp. will be used only  in connection with the Annual General
Meeting and with the processing of the related registration.

A  shareholder who  is present  at the  Annual General  Meeting has the right to
request  information with respect to the matters to be considered at the meeting
pursuant to chapter 5, section 25 of the Finnish Companies Act.

2. Proxy representative and powers of attorney

A  shareholder may participate in the Annual General Meeting and exercise his or
her rights at the meeting by way of proxy representation.

A  proxy representative shall produce  a dated proxy document  or otherwise in a
reliable manner demonstrate his or her right to represent the shareholder at the
Annual  General Meeting. When  a shareholder participates  in the Annual General
Meeting  by means of several  proxy representatives representing the shareholder
with  shares in  different securities  accounts, the  shares by which each proxy
representative represents the shareholder shall be identified in connection with
the registration for the Annual General Meeting.

Proxy  documents should  be delivered  in original  form to  the company, at the
address  of Biotie Therapies  Corp. / Virve  Nurmi, Joukahaisenkatu 6, FI-20520
Turku, Finland, before the last date for registration, 28 April 2016.

3. Holders of nominee registered shares

A holder of nominee-registered shares has the right to participate in the Annual
General  Meeting by virtue of holding shares, based  on which he or she would be
entitled  to be registered in the shareholders'  register of the company held by
Euroclear Finland Ltd on the record date of the Annual General Meeting, 21 April
2016. The  right  to  participate  in  the  Annual  General Meeting requires, in
addition,   that  the  shareholder,  with  respect  to  such  shares,  has  been
temporarily  registered in the shareholders'  register held by Euroclear Finland
Ltd  by no later than 28 April 2016 at 10.00 a.m. (Finnish time). Such temporary
registration constitutes a due registration for the Annual General Meeting.

A  holder of nominee registered shares is  advised to request without delay from
his  or  her  custodian  bank  necessary  instructions  regarding  the temporary
registration  in the shareholders' register of the company, the issuing of proxy
documents  and  the  registration  for  the  Annual General Meeting. The account
management  organization of  the custodian  bank has  to register  the holder of
nominee  registered  shares,  who  wants  to  participate  in the Annual General
Meeting,  to  be  temporarily  entered  into  the  shareholders' register of the
company by no later than the time stated above.

4. Other information

On  the date of this  notice for the Annual  General Meeting, 12 April 2016, the
total  number of shares and votes in Biotie Therapies Corp. is 1,089,608,083. On
the  date of  this notice  Biotie Therapies  Corp. and  its subsidiaries hold in
aggregate 106,088,336 own shares.

In Turku, 12 April 2016

Biotie Therapies Corp.

Board of Directors



For further information, please contact:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:

Nasdaq Helsinki Ltd
Main Media


[HUG#2002636]